Search ARM

Q3 2017


Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam ultricies neque sit amet tortor malesuada tristique. Suspendisse cursus scelerisque lacus, sit amet mollis mi hendrerit non. Mauris at imperdiet libero. Vestibulum commodo ex lorem, ac tincidunt lectus pharetra vel. Vivamus ut lacus sed tortor commodo bibendum. Morbi ultrices elit ac purus egestas vestibulum. Nam consectetur malesuada ipsum, sit amet mattis lorem iaculis at.


Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam ultricies neque sit amet tortor malesuada tristique. Suspendisse cursus scelerisque lacus, sit amet mollis mi hendrerit non. Mauris at imperdiet libero. Vestibulum commodo ex lorem, ac tincidunt lectus pharetra vel. Vivamus ut lacus sed tortor commodo bibendum. Morbi ultrices elit ac purus egestas vestibulum. Nam consectetur malesuada ipsum, sit amet mattis lorem iaculis at.

Global Landscape

843+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies

Financings

Total Q3 2017 Global Financings

Total Global Financing

102%

Increase from Q3 2016

Gene & Gene-modified
Cell Therapy

167%

Increase from Q3 2016

Cell Therapy

295%

Increase from Q3 2016

Tissue Engineering

79%

Decrease from Q3 2016

Total Global Financings by Type, by Year

934

Clinical trials underway
worldwide by the end of Q3 2017

PH. 1

307

PH. 2

548

PH. 3

79

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology: Q3 2017

Gene & Gene-modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q3 2017